Reserpine

References

• 1) Inhibitory and Resistance-Modifying Potential of Plant-Based Alkaloids Against Methicillin-Resistant Staphylococcus aureus (MRSA)
  • M. Mohtar, S.A. Johari, A.R. Li, M.M. Isa, S. Mustafa, A.M. Ali, D.F. Basri, Curr. Microbiol. 2009, 59, 181.
• 2) Identification of natural compounds which inhibit biofilm formation in clinical isolates of Klebsiella pneumoniae.
  • H. Magesh, A. Kumar, A. Alam, Priyam, U. Sekar, V. N. Sumantran, R. Vaidyanathan, Indian J. Exp. Biol. 2013, 51, 764.
• 3) Effectiveness of efflux pump inhibitors as biofilm disruptors and resistance breakers in gram-negative (ESKAPEE) bacteria
  • A. Reza, J. M. Sutton, K. M. Rahman, Antibiotics 2019, 8, 229.


Application
Reserpine: A Central Nervous System Depressant and an Inhibitor of Multidrug Efflux Pumps in Bacteria
Reserpine is an alkaloid of rauwolfia sharing the yohimbine [Y0002] pentacyclic skeleton. Pharmacological studies have revealed that reserpine is a central nervous system depressant. Reserpine depletes stores of catecholamines (dopamine [A0305], noradrenaline [A0906] and adrenaline [A0173]) and 5-hydroxytryptamine [S0370] by inhibiting their accumulation in many organs, including the brain and adrenal medulla. The depression of the central nervous system results in a decreased heart rate and a lowering of arterial blood pressure.
In addition, some studies have reported that reserpine enhances the in vitro activity of fluoroquinolones, such as norfloxacin [N0817], ciprofloxacin [C2227, C2510] and sparfloxacin [S0840], against strains of Staphylococcus aureus expressing distinct efflux-related multidrug resistance pumps. (The product is for research purpose only.)

References

• Study of the relationship between the neurotransmitter store and adrenergic nerve block induced by reserpine and guanethidine
  • T. E. Gaffney, C. A. Chidsey, E. Braunwald, Circ Res. 1963, 12, 264.
• The reserpine receptor (a review)
  • A. Giachetti, P. A. Shore, Life Sciences 1978, 23, 89.
• How reserpine and chlorpromazine act: the impact of key discoveries on the history of psychopharmacology (a review)
  • G. Curzon, Trends Pharmacol. Sci. 1990, 11, 61.
• The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
  • F. J. Schmitz, A. C. Fluit, M. Lückefahr, B. Engler, B. Hofmann, J. Verhoef, H. P. Heinz, U. Hadding, M. E. Jones, J. Antimicrob. Chemother. 1998, 42, 807.
• A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus
  • S. Gibbons, M. Oluwatuyi, G. W. Kaatz, J. Antimicrob. Chemother. 2003, 51, 13.
• Reserpine (a review on the description, properties, degradation, metabolism, and analysis of reserpine)
  • R. E. Schirmer, Anal. Profiles Drug Subst. 1984, 13, 737.


Application
Reagen for myalgia model

References

• Depletion and recovery of neuronal monoamine storage in rats of different ages treated with reserpine
  • F. Ponzio, G. Achilli, G. Calderini, P. Ferretti, C. Perego, G. Toffano, S. Algeri, Neurobiol. Aging. 1984, 5, 101.
• Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia
  • Y. Nagakura, T. Oe, T. Aoki, N. Matsuoka, Pain 2009, 146, 26.


Application
Reagent for pain model

Reference

• Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: A putative animal model of fibromyalgia
  • Y. Nagakura, T. Oe, T. Aoki, N. Matsuoka, Pain 2009, 146, 26.


Application
Reagent for schizophrenia model

References

• Electroconvulsive shock: sustained decrease in norepinephrine uptake affinity in a reserpine model of depression
  • E. D. Hendley, B. L. Welch, Life Sci. 1975, 16, 45.
• Prejudices in pharmacology and pharmacotherapy: reserpine as a model for experimental research in depression
  • H. J. Bein, Pharmakopsychiatry Neuropsychopharmakol. 1978, 11, 289.
• Evaluation of the face validity of reserpine administration as an animal model of depression--Parkinson's disease association
  • L. L. Skalisz, V. Beijamini, S. L. Joca, M. A. Vital, C. Da Cunha, R. Andreatini, Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26, 879.
• Antidepressant-like Effect of Tetrahydroisoquinoline Amines in the Animal Model of Depressive Disorder Induced by Repeated Administration of a Low Dose of Reserpine: Behavioral and Neurochemical Studies in the Rat
  • L. Antkiewicz-Michaluk, A. W?sik, E. Możdżń, I. Romańska, J. Michaluk, Neurotox. Res. 2014, 26, 85.


PubMed Litterature